Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. ((3s)-3-((2s)-2-((4-methoxy-1h-indol-2-yl)formamido)-4-methylpentanamido)-2-oxo-4-((3s)-2-oxopyrrolidin-3-yl)butoxy)phosphonic Acid
2. (14c)-pf-07304814
3. 14c Labeled Pf-07304814
4. 14c-pf-07304814
5. 4-methoxy-n-((2s)-4-methyl-1-oxo-1-(((2s)-3-oxo-1-((3s)-2-oxopyrrolidin-3-yl)-4-(phosphonooxy)butan-2-yl)amino)pentan-2-yl)-1h-indole-2-carboxamide
6. C14-pf-07304814
7. N-((1s)-1-((((1s)-3-hydroxy-2-oxo-1-(((3s)-2-oxopyrrolidin-3-yl)methyl)propyl)amino)carbonyl)-3-methylbutyl)-4-methoxy-1h-indole-2-carboxamide
8. Pf-00835231
9. Pf-07304814
10. Pf-835231
1. Pf-07304814
2. Lufotrelvir [usan]
3. Xj51yob1sc
4. Pf07304814
5. 2468015-78-1
6. (3s)-3-({n-[(4-methoxy-1h-indol-2-yl)carbonyl]-l-leucyl}amino)-2-oxo-4-[(3s)-2-oxopyrrolidin-3-yl]butyl Dihydrogen Phosphate
7. [(3~{s})-3-[[(2~{s})-2-[(4-methoxy-1~{h}-indol-2-yl)carbonylamino]-4-methyl-pentanoyl]amino]-2-oxidanylidene-4-[(3~{r})-2-oxidanylidene-3,4-dihydropyrrol-3-yl]butyl] Dihydrogen Phosphate
8. 1h-indole-2-carboxamide, 4-methoxy-n-((1s)-3-methyl-1-((((1s)-2-oxo-1-(((3s)-2-oxo-3-pyrrolidinyl)methyl)-3-(phosphonooxy)propyl)amino)carbonyl)butyl)-
9. 4-methoxy-n-((2s)-4-methyl-1-oxo-1-(((2s)-3-oxo-1-((3s)-2-oxopyrrolidin-3-yl)-4-(phosphonooxy)butan-2-yl)amino)pentan-2-yl)-1h-indole-2-carboxamide
10. Unii-xj51yob1sc
11. Lufotrelvir [inn]
12. Chembl4802214
13. Gtpl11249
14. Chebi:173073
15. Bdbm510049
16. Dtxsid501337108
17. Ex-a4702
18. Who 12095
19. Pf-07304814 [who-dd]
20. Hy-138078
21. Cs-0144500
22. Pf 07304814
23. (3s)-3-{[(2s)-2-{[(4-methoxy-1h-indol-2-yl)carbonyl]amino}-4-methylpentanoyl]amino}-2-oxo-4-[(3s)-2-oxopyrrolidin-3-yl]butyl Dihydrogen Phosphate
24. [(3s)-3-[(2s)-2-[(4-methoxy-1h-indol-2-yl)formamido]-4-methylpentanamido]-2-oxo-4-[(3s)-2-oxopyrrolidin-3-yl]butoxy]phosphonic Acid
| Molecular Weight | 552.5 g/mol |
|---|---|
| Molecular Formula | C24H33N4O9P |
| XLogP3 | 0.5 |
| Hydrogen Bond Donor Count | 6 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 13 |
| Exact Mass | 552.19851564 g/mol |
| Monoisotopic Mass | 552.19851564 g/mol |
| Topological Polar Surface Area | 196 Ų |
| Heavy Atom Count | 38 |
| Formal Charge | 0 |
| Complexity | 927 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
The structure of PF-07304814 contains a phosphate group, allowing the compound to be soluble and then subsequently cleaved in tissue by alkaline phosphatase. This step allows for the release of PF-00835231, which is the compound that exerts anti-viral activity against the 3CL protease of SARS-CoV-2. The active compound, PF-00835231, was shown to have potent and broad-spectrum inhibitory activity against numerous coronavirus 3CL proteases.
ABOUT THIS PAGE
91
PharmaCompass offers a list of Lufotrelvir API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Lufotrelvir manufacturer or Lufotrelvir supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Lufotrelvir manufacturer or Lufotrelvir supplier.
PharmaCompass also assists you with knowing the Lufotrelvir API Price utilized in the formulation of products. Lufotrelvir API Price is not always fixed or binding as the Lufotrelvir Price is obtained through a variety of data sources. The Lufotrelvir Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Lufotrelvir manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lufotrelvir, including repackagers and relabelers. The FDA regulates Lufotrelvir manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lufotrelvir API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Lufotrelvir supplier is an individual or a company that provides Lufotrelvir active pharmaceutical ingredient (API) or Lufotrelvir finished formulations upon request. The Lufotrelvir suppliers may include Lufotrelvir API manufacturers, exporters, distributors and traders.
Lufotrelvir Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lufotrelvir GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lufotrelvir GMP manufacturer or Lufotrelvir GMP API supplier for your needs.
A Lufotrelvir CoA (Certificate of Analysis) is a formal document that attests to Lufotrelvir's compliance with Lufotrelvir specifications and serves as a tool for batch-level quality control.
Lufotrelvir CoA mostly includes findings from lab analyses of a specific batch. For each Lufotrelvir CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lufotrelvir may be tested according to a variety of international standards, such as European Pharmacopoeia (Lufotrelvir EP), Lufotrelvir JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lufotrelvir USP).
